NCT00776009
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
See it on ClinicalTrials.gov ↗165 people
43%
57%
71 womenmiddle line = equal numbers94 men
- Phase
- PHASE4
- Paid for by
- Novartis Pharmaceuticals
- Finished
- 2008-12
- Health conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Who could join
- Anyone
- Ages
- 6 Years – 12 Years
- Average age
- mean 9.6 Years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- Age limit under 65
Older women were turned away, even though they often take this medicine.
“Maximum age: 12 Years.”
- No seizures
Women with epilepsy or past seizures were turned away.
“History of seizure disorder.”
- No mental health conditions
Women with depression, bipolar disorder or other mental health conditions were turned away.
“A history of psychiatric illness or substance use disorder (e.g., schizophrenia, bipolar disorder, autism, abuse or dependence, depression, severe Conduct Disorder or severe Oppositional defiant disorder)”
Study titles and rules are shown in their original English.